Mexico launches leukaemia therapy/testing plan
This article was originally published in Clinica
Executive Summary
A Mexican initiative to provide universal treatment for chronic myeloid leukaemia will also cover the associated therapy-monitoring testing. So promised the health ministry of the "very expensive laboratory tests required by patients every three or four months". The project, announced last week, is being is being co-ordinated by the national cancer institute (INCAN), with the support of Mexico's AMANC Foundation and Novartis.